Q-omics provides the consensus-scored PLXNA3 profile across patient tissues and cancer cell-line models. PLXNA3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PLXNA3 is differentially expressed in 18, with the highest sampling consensus in KIRC. Additionally, PLXNA3 RNA expression shows 19,595 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where PLXNA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLXNA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLXNA3 survival associations across molecular data types. PLXNA3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (12) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLXNA3 RNA expression–survival associations across cancer types. High PLXNA3 expression shows unfavorable associations in MESO, UVM, LGG, LUSC and COAD, but favorable associations in UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for PLXNA3 RNA expression.
This table summarizes PLXNA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLXNA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLXNA3 shows higher tumor expression in KIRC, KIRP, COAD, HNSC, THCA and LIHC. The KIRC box plot shows higher PLXNA3 RNA expression in tumor versus normal tissue (log2 FC = +1.141, t-test p < 0.001).
This table shows molecular features associated with PLXNA3 in patient tissues and cancer cell lines. In patient samples, PLXNA3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLXNA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
